AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial
CompanyDrug

AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial

MSD's Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review
CompanyDrug

MSD’s Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review

Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases
CompanyDeals

Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases

Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development
CompanyDeals

Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development

BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets
CompanyDeals

BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets

DaAn Gene Co., Ltd Receives NMPA Approval for Genetic Deafness Gene Detection Kit
CompanyMedical Device

DaAn Gene Co., Ltd Receives NMPA Approval for Genetic Deafness Gene Detection Kit

MediLink Therapeutics' YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer
CompanyDrug

MediLink Therapeutics’ YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer

BMS Regains Exclusive Rights to ABZ-706 in Greater China
CompanyDeals

BMS Regains Exclusive Rights to ABZ-706 in Greater China

Everest Medicines' Nefecon Receives First Prescription for IgAN Treatment in Adults
CompanyDrug

Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults

FDA Approves Xcovery Holdings' Ensartinib for Untreated ALK-Positive NSCLC Patients
CompanyDrug

FDA Approves Xcovery Holdings’ Ensartinib for Untreated ALK-Positive NSCLC Patients

NT Medical Instruments to Acquire Controlling Stake in Weiqiang Medical Technology for RMB 230 Million
CompanyDeals

INT Medical Instruments to Acquire Controlling Stake in Weiqiang Medical Technology for RMB 230 Million

Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma
CompanyDrug

Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma